Lipid Screening Study
Prospective Screening for Elevated Lipoprotein(a) in an Adult Primary Care Population
1 other identifier
observational
35
1 country
1
Brief Summary
The purpose of this pilot study is to estimate the prevalence of elevated Lipoprotein (a) in an adult primary care population and to describe the distribution of atherogenic lipid markers within this cohort. This pilot study will provide preliminary data to inform future cardiovascular risk assessment initiatives in primary care.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started May 2026
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 5, 2026
CompletedFirst Submitted
Initial submission to the registry
May 6, 2026
CompletedFirst Posted
Study publicly available on registry
May 12, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 16, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
July 28, 2026
CompletedJuly 30, 2026
July 1, 2026
2 months
May 6, 2026
July 28, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Lipoprotein(a) prevalence in Adults
The purpose of this pilot study is to estimate the prevalence of elevated Lipoprotein (a) in an adult primary care population and to describe the distribution of atherogenic lipid markers within this cohort. This pilot study will provide preliminary data to inform future cardiovascular risk assessment initiatives in primary care.
3 months
Interventions
The study procedures include a single venipuncture (10 mL) performed for research purposes to obtain blood samples for laboratory analysis of lipoprotein(a), apolipoprotein B, and a lipid panel with reflex to direct Low-Density Lipoprotein (LDL) cholesterol measurement. The lipid panel includes total cholesterol, triglycerides, High-Density Lipoprotein (HDL) cholesterol, and calculated non-HDL cholesterol and cholesterol/HDL ratio. If triglyceride levels exceed the laboratory threshold for accurate calculation of LDL cholesterol, a direct LDL cholesterol assay will be performed per standard laboratory protocol. In addition, the study includes abstraction of demographic and clinical information from the electronic medical record (EMR), including age, sex, BMI, comorbid conditions, and cardiovascular history. All laboratory analyses will be performed using standard clinical laboratory assays. No investigational drugs or medical devices are being used in this study.
Eligibility Criteria
As any adult patient can be enrolled, no pre-screening will be done. UCFH only sees adult patients.
You may qualify if:
- Adults aged 18 years or older
- Receiving care at UCF Health primary care clinic
- Able to understand and provide informed consent and HIPAA authorization
You may not qualify if:
- Patient self discloses any medical condition that would make venipuncture unsafe
- Pregnant women
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Central Florida
Orlando, Florida, 32827, United States
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Stephanie Perez, MSN, MBA, ARNP, CLS, BHCN
University of Central Florida
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 6, 2026
First Posted
May 12, 2026
Study Start
May 5, 2026
Primary Completion
July 16, 2026
Study Completion
July 28, 2026
Last Updated
July 30, 2026
Record last verified: 2026-07